Last updated: October 16, 2026
Nipent, the brand name for pentostatin, is a mature oncology product with limited revenue potential and disproportionate supply importance in hairy cell leukemia. Its original U.S. patent and regulatory exclusivity have expired, and public company filings do not disclose standalone Nipent revenue. The commercial market is now shaped by generic availability, manufacturing continuity, hospital procurement, and competition from cladribine rather than by patent protection.
Pentostatin remains clinically relevant for selected patients with hairy cell leukemia and related lymphoid malignancies. Its financial trajectory is best characterized as a late-life, low-volume injectable product with weak pricing power, periodic shortage exposure, and limited strategic value unless bundled into a broader hospital oncology portfolio.
What is Nipent and how is pentostatin used?
Nipent is an intravenous formulation of pentostatin, a purine nucleoside analog. The U.S. Food and Drug Administration approved pentostatin for the treatment of adult patients with hairy cell leukemia in 1991. The approved regimen is 4 mg/m² administered intravenously every other week, subject to renal-function and toxicity considerations.[1]
What diseases does pentostatin treat?
Pentostatin is primarily associated with:
- Hairy cell leukemia
- Relapsed or refractory hairy cell leukemia
- Selected T-cell and B-cell lymphoid malignancies in off-label practice
- Certain cases where cladribine is unsuitable or unavailable
Hairy cell leukemia is a rare B-cell leukemia. U.S. incidence is generally estimated at approximately 1,000 new cases annually, although published estimates vary by methodology and reporting period.[2] The small patient population constrains total market size.
Pentostatin is administered in specialized oncology settings. The product is not a chronic retail prescription and does not benefit from broad primary-care utilization. Demand is concentrated among hematology practices, academic centers, hospitals, and specialty distributors.
What is the FDA status of Nipent?
The FDA approved Nipent under New Drug Application 019604. The product’s regulatory exclusivity is long expired. FDA records identify the product as an older oncology injectable with a history of market discontinuation and generic-equivalent availability issues.[1,3]
Is Nipent still marketed in the United States?
Commercial availability has changed over time. Brand Nipent has been associated with Hospira, which Pfizer acquired in 2015. Public FDA discontinuation records and product listings indicate that the brand has not functioned as a growth product in the U.S. market. Pentostatin may still be available through generic or institutional supply channels, depending on the period and distributor inventory.[3]
A discontinuation designation in FDA records does not necessarily mean that the active ingredient is permanently unavailable. It indicates that the listed product is no longer being marketed under the relevant application or product configuration. For pentostatin, procurement risk is more important than brand loyalty because treatment centers can face limited supplier choice.
What is the Orange Book status of Nipent?
Nipent’s original patent and regulatory exclusivity have expired. The product does not have a modern patent moat comparable with recently approved oncology drugs. Any remaining Orange Book relevance would relate to historical listings, formulation records, or generic approval pathways rather than active exclusivity.
For commercial analysis, pentostatin should be treated as an off-patent injectable oncology drug. The competitive question is whether an approved supplier can maintain production and regulatory compliance, not whether a branded patent owner can block generic entry.
When did Nipent lose exclusivity?
Pentostatin’s U.S. exclusivity ended many years ago. The product was approved in 1991, and any orphan-drug exclusivity associated with the approval would have expired in the 1990s. The standard small-molecule patent life also predates the current commercial period.
| Milestone |
Approximate timing |
Commercial effect |
| U.S. approval of Nipent |
1991 |
Established pentostatin as an approved hairy-cell-leukemia therapy |
| Orphan exclusivity period |
1990s |
Temporarily restricted approval of the same drug for the same indication |
| Original patent protection |
Expired years ago |
Removed branded market exclusivity |
| Generic competition |
Mature market period |
Shifted pricing power to suppliers and purchasers |
| Brand commercial decline |
2010s-2020s |
Reduced investment in standalone brand promotion |
| Current market |
Late-life injectable |
Availability and manufacturing capacity drive access |
No active patent estate is known to support a premium branded strategy for Nipent in the United States. Patent risk is therefore low for generic entrants, while manufacturing and regulatory risk remain material.
How large is the pentostatin market?
No reliable public source reports global or U.S. Nipent revenue as a standalone line item. Pfizer and Hospira financial disclosures have historically reported results at broader product, segment, or business-unit levels rather than identifying Nipent sales separately.[4]
The addressable market is structurally small:
- Hairy cell leukemia is rare.
- Pentostatin is used in a narrow therapeutic setting.
- Treatment is intermittent rather than lifelong.
- Cladribine is a major alternative.
- Hospitals and group purchasing organizations exert pricing pressure.
- Generic substitution limits brand premiums.
The product can still generate revenue because oncology injectables carry high per-course value relative to unit volume. Yet the absolute revenue ceiling is limited by patient numbers and clinical substitution.
What is the likely revenue trajectory for Nipent?
The product’s revenue trajectory is likely to have followed four stages:
Launch and clinical adoption
After approval, pentostatin gained adoption as a highly active treatment for hairy cell leukemia. Its clinical value was strongest when physicians sought durable responses with an established purine analog.
Mature branded sales
The product entered a stable niche market with recurring but low patient volume. Revenue would have depended on treatment-center penetration, pricing, supply reliability, and use in relapsed disease.
Generic and portfolio rationalization
After exclusivity expired, generic competition reduced the value of standalone brand promotion. Ownership changes involving Mayne and Hospira, followed by Pfizer’s acquisition of Hospira, placed the product inside larger hospital-drug portfolios.[5]
Late-life supply economics
At this stage, manufacturing cost, minimum batch size, sterility controls, vial demand, and regulatory maintenance become more important than market expansion. A product can remain medically necessary while generating insufficient revenue to support multiple suppliers.
How does Nipent compare with cladribine?
Cladribine is the principal clinical and commercial comparator for pentostatin in hairy cell leukemia. Both are purine analogs, but cladribine has often been favored because of its efficacy, treatment convenience, and guideline positioning.
| Attribute |
Pentostatin |
Cladribine |
| Drug class |
Purine nucleoside analog |
Purine nucleoside analog |
| Main use |
Hairy cell leukemia |
Hairy cell leukemia |
| Administration |
Repeated intravenous dosing, commonly every two weeks |
Regimen varies by formulation and protocol |
| Market position |
Mature, niche, supply-sensitive |
Stronger first-line reference position in many treatment settings |
| Patent position |
Long expired |
Depends on formulation and product-specific rights |
| Commercial risk |
Supplier withdrawal and shortages |
Competition among formulations and treatment protocols |
| Substitution pressure |
High |
Lower in settings where guidelines favor cladribine |
The National Comprehensive Cancer Network and specialty literature generally place cladribine and pentostatin among effective purine analog approaches, with treatment selection affected by disease status, immunosuppression risk, comorbidities, and prior therapy.[6]
Pentostatin’s commercial weakness is not a lack of clinical activity. It is the combination of a small indication, an off-patent product, and a competing therapy with strong physician familiarity.
What generic entry risks exist for Nipent?
Generic entry risk is high in legal terms and moderate in practical terms.
Legal entry risk
Because the original exclusivity period has expired, a generic manufacturer does not face a meaningful branded patent barrier. A Paragraph IV challenge would have been relevant during the patent-protected period, but it is not the central commercial issue today.
The absence of a current patent barrier does not guarantee launch. Generic manufacturers still must address:
- Sterile injectable manufacturing
- FDA chemistry, manufacturing, and controls requirements
- Stability and container-closure validation
- Low annual volume
- Potentially unattractive batch economics
- Hospital contracting and distributor access
- Shortage-management obligations
Practical entry risk
Pentostatin is a difficult generic product economically because demand is narrow and manufacturing is technically demanding. The market may support only a small number of suppliers. That creates a paradox: legal barriers are low, but supply resilience can be weak.
A new entrant would likely need a broader oncology injectable portfolio to justify commercial infrastructure. Pentostatin alone is unlikely to support a large sales force or dedicated manufacturing line.
What patent protection covers Nipent today?
No active U.S. patent estate is expected to protect the original pentostatin molecule or its basic approved injectable use. Any residual patent activity would more likely involve:
- Manufacturing processes
- Crystalline or solid-state forms
- Packaging or container systems
- New combinations
- Alternative dosing schedules
- Regional rights outside the United States
These categories have limited commercial importance unless tied to an approved, differentiated product. The original Nipent product is not protected by a modern formulation patent strategy comparable with newer long-acting oncology products.
Are method-of-use patents relevant?
Method-of-use patents could theoretically cover a new indication, dosing schedule, combination, or patient subgroup. In practice, pentostatin’s commercial potential is constrained by its mature clinical profile and the small size of the underlying diseases.
A method-of-use strategy could be relevant if a sponsor developed a new regimen with regulatory approval. Without a new approval and enforceable claims, clinical use alone would not create meaningful exclusivity.
What manufacturing and supply barriers affect pentostatin?
Manufacturing is the main commercial barrier.
Pentostatin is an injectable oncology product. Suppliers must maintain aseptic processing, validated sterilization and filling controls, quality systems, and reliable active pharmaceutical ingredient supply. A low-volume product can become vulnerable when:
- A manufacturer closes a facility
- A production batch fails
- An active ingredient supplier exits
- Demand forecasts do not justify inventory
- A product is deprioritized after an acquisition
- Regulatory remediation delays release
Shortage exposure can increase the product’s short-term economic value for a supplier, but it can also accelerate substitution to cladribine or other therapies. Hospitals typically respond to recurring supply disruption by reducing formulary dependence on the affected product.
Which companies have been associated with Nipent and pentostatin?
The commercial history has included the original innovator and later hospital-drug manufacturers. Hospira became the best-known U.S. commercial owner of the product before Pfizer acquired Hospira. Generic pentostatin supply has also depended on specialized injectable manufacturers and regional distributors.[3,4,5]
The market is therefore less concentrated around an originator than around whichever supplier maintains an approved, available presentation. Brand ownership has limited value if hospitals cannot obtain the product consistently.
What litigation and settlement agreements affect Nipent?
No major current patent litigation or settlement agreement is central to the U.S. pentostatin market. The relevant legal history is the expiration of original exclusivity and the transition from branded supply to generic or late-life portfolio management.
Any historical Paragraph IV activity would have commercial significance only if tied to a still-enforceable patent. For current diligence, litigation risk is lower than regulatory, manufacturing, and supply-chain risk.
What is the financial outlook for Nipent?
The financial outlook is low-growth to declining, with episodic upside from supply tightness rather than volume expansion.
| Financial driver |
Direction |
Effect |
| Patient population |
Stable, very small |
Limits revenue ceiling |
| Brand pricing power |
Declining |
Generic and hospital purchasing pressure |
| Patent protection |
None of practical significance |
Prevents exclusivity-based premium |
| Generic competition |
Present or possible |
Compresses price |
| Manufacturing cost |
High relative to volume |
Weakens margins |
| Shortage conditions |
Volatile |
Can increase price but reduce utilization |
| Competitive therapy |
Strong, especially cladribine |
Limits share growth |
| Portfolio value |
Selective |
More attractive inside a broad injectable portfolio |
A supplier could still earn acceptable margins if it controls a low-cost sterile facility, has limited direct competition, and secures hospital contracts. The product is less attractive for a standalone specialty-pharma investment because revenue is difficult to scale and supply failures can permanently damage demand.
What generic launch scenarios are plausible?
Scenario 1: Stable niche supply
One or two suppliers maintain production, and pentostatin remains available for physicians who prefer it or require an alternative to cladribine. Revenue remains small but predictable.
Scenario 2: Intermittent shortage
A manufacturing disruption causes temporary scarcity. Hospitals allocate available inventory to urgent cases, while some physicians shift patients to cladribine. Pentostatin revenue becomes volatile and long-term share declines.
Scenario 3: Commercial withdrawal
The last supplier exits because of low volume or unfavorable manufacturing economics. Pentostatin becomes difficult to source, with use limited to institutions able to obtain specialty inventory or import product where legally permitted.
Scenario 4: Specialty revival
A supplier acquires or relaunches the product with reliable manufacturing and improved distribution. This could stabilize revenue but is unlikely to create high growth without a new indication or differentiated regimen.
How strong is the Nipent patent estate?
The patent estate is weak for present-day commercial purposes. The product is a mature, off-patent small molecule with no meaningful U.S. exclusivity barrier. Its strategic value comes from clinical familiarity and supply scarcity, not enforceable patent rights.
The stronger diligence questions are:
- Is an approved supplier active?
- Is product listed as available in the target jurisdiction?
- Are there current shortages?
- Can the manufacturer maintain sterile production?
- Does the supplier have hospital contracts?
- Is cladribine preferred in current treatment guidelines?
Key Takeaways
- Nipent is pentostatin, an FDA-approved purine analog for hairy cell leukemia.
- U.S. approval dates to 1991, and original patent and regulatory exclusivity have expired.
- Public filings do not provide standalone Nipent revenue.
- The market is small because hairy cell leukemia is rare and treatment is intermittent.
- Cladribine is the principal clinical competitor and limits pentostatin’s growth potential.
- Generic-entry risk is high, but manufacturing barriers make supply less predictable than patent status suggests.
- The main commercial risks are sterile manufacturing, supplier withdrawal, low-volume economics, and hospital substitution.
- No major current patent litigation or settlement is central to the product’s U.S. market.
- Pentostatin is more valuable as part of a broad hospital-injectable portfolio than as a standalone branded asset.
- The base-case financial trajectory is mature to declining revenue with potential short-term volatility during shortages.
FAQs About Nipent Market Dynamics and Pentostatin Commercial Risk
Is Nipent still protected by patents?
No meaningful original U.S. patent protection remains. Pentostatin is a mature off-patent product.
Does FDA exclusivity still block pentostatin generics?
No. Any orphan-drug or other regulatory exclusivity associated with the original approval expired years ago.
Is pentostatin more commercially attractive than cladribine?
Generally no. Cladribine has a stronger treatment position in many hairy cell leukemia protocols, while pentostatin has a smaller, supply-sensitive market.
Can a company obtain orphan-drug exclusivity for a new pentostatin indication?
Potentially, but a new exclusivity period would require a qualifying new indication and FDA approval. Existing approval of pentostatin would not itself create new exclusivity.
What is the greatest investment risk for a pentostatin supplier?
The principal risk is uneconomic sterile manufacturing at low annual volume. Regulatory compliance, batch failure, and hospital substitution can compound that risk.
References
-
U.S. Food and Drug Administration. (1991). Nipent (pentostatin) prescribing information. FDA.
-
National Cancer Institute. (n.d.). Hairy cell leukemia: Statistics. Surveillance, Epidemiology, and End Results Program.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Nipent, NDA 019604; FDA drug product and discontinuation records. FDA.
-
Pfizer Inc. (2015-2023). Annual reports and Form 10-K filings. Pfizer Investor Relations.
-
Pfizer Inc. (2015). Pfizer completes acquisition of Hospira. Pfizer Newsroom.
-
National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Hairy Cell Leukemia. NCCN.
